Sdi Share Discussion Threads

[bookbroker] 26/2/2014 08:28

Thing is, can this management do that, are they capable, they disappointed badly last year, is this recent acquisition a defensive one, this was driven up on the placing, now the reality, they have been talking the talk, now they gotta walk the walk, those forecasts look somewhat optimistic on the basis of last year, I see this management as prone to gaffes, wished I had sold last of holding last week, this is one co. that the directors should look at the share price to gauge their performance, seeing as I'm sure they are more than adequately remunerated!

[adamb1978] 25/2/2014 13:17

Bookbroker - as you say, the fundraising last year is irrelevant when thinking about the acquisition given a high proportion was financed with paper.

Unconcerned about today's fall - just over £20k shares have changed hands.

SDI dont need to grow the top line too crazily for the share price to look way too cheap

[bookbroker] 25/2/2014 12:00

Not really sure how this co. can make such a large acquisition relative to size, albeit with stock, when the whole point of their fundraising last year was principally to pay down the loan note, and for working capital purposes, was going to buy more but now looking at the moves today I'm beginning to think discretion the better part!

[5310carraroe] 25/2/2014 11:54

No problem to get hold of stock now

[gnnmartin] 25/2/2014 11:41

Indeed, what was all that about?

[bookbroker] 25/2/2014 11:32

Now's your chance Beaufort, down 30% in three days, strange moves!

[beaufort1] 20/2/2014 10:34

Very hard to buy stock in any amount at the moment. B1

[gnnmartin] 20/2/2014 10:22

Well that's been a spectacular rise so far. I'm a bit disappointed, as I had planned to buy more in March (no funds available until then).
Nigel Martin

[mudbath] 14/2/2014 17:05

The profile of SDI is uncannily similar to that of Kromek,except that KMK has a market cap fifteen times larger.
Indeed we even recruited one of their Directors,Mike Creedon, to eventually become our CEO.

The undermentioned new product launch should further stimulate revenues.

Thursday 16 January 2014

Cambridge, UK: Scientific Digital Imaging's [SDI's] Syngene Division, a world-leading manufacturer of image analysis solutions is delighted to announce the new G:BOX Chemi XRQ multi-functional image analysis system is now available. Utilising the latest imaging technology and software, the G:BOX Chemi XRQ system is ideal for scientists needing a cost-efficient system for quickly and easily imaging a range of gel or blot types.

The G:BOX Chemi XRQ features a new generation, high resolution, high quantum efficiency (a massive 73% quantum efficiency at 425nm) and low noise CCD camera with 4 megapixel imaging capabilities inside a light tight darkroom. This means the G:BOX Chemi XRQ can accurately visualise and separate faint and bright bands on one gel or blot with ease.

The cleverly designed modular system includes motor-driven lenses and filter wheel with the option of including red, blue, green, IR LEDs and transillumination lighting, making G:BOX Chemi XRQ the versatile choice for chemiluminescent Westerns, as well as standard fluorescence and colorimetric imaging tasks.

The G:BOX Chemi XRQ, which can be supplied with a computer or researchers can use their own laboratory computer, is controlled by touch screen via new streamlined GeneSys software. This guides scientists through image set-up using its database of imaging conditions for hundreds of commercially available dyes, thus saving researchers the time and effort of looking up recommended detection conditions.

GeneSys rapidly optimises filters and lighting according to the hardware inside the G:BOX Chemi XRQ and the image is calibrated according to the gel or blot's size allowing scientists to take advantage of the camera's full resolving power. Researchers then select their combination and the software instructs the G:BOX Chemi XRQ to automatically set-up the filters and lighting to generate sharp, clear gel or blot images. For even faster, automated image capture, GeneSys includes a unique researcher 'protocol save' feature enabling one-click recall of frequently used imaging settings.

Laura Sullivan, Syngene's Divisional Manager stated: "In these budget constrained times, scientists' feedback is that they need an image analyser which is versatile enough to be used by a large number of researchers of different skill levels so has to be easy to set up, allow storage of specific image protocols and perform well with a range of different dyes on gels and blots."

Laura continued: "This is challenging but utilising our years of expertise, we have combined a camera, which has the highest quantum efficiency of any in this imager class, with incredible new GeneSys image capture software to develop the G:BOX Chemi XRQ. The result is that researchers looking for an affordable image analysis system that rapidly delivers high quality, chemiluminescence blot, fluorescence and colorimetric gel images time after time won't want any other system, when they see a G:BOX Chemi XRQ in action."

[mudbath] 14/2/2014 11:27

SDI could be a stellar performer over the next year or two.
With superb,niche technologies(as detailed in Nick2008's excellent header),the recent refresh and repricing of their products should stimulate revenues,as will the growing popularity of astronomy,given no little boost by the BBC's Stargazing LIVE.
Today's announcement of the Opus Instruments acquisition is very interesting given Ken Ford's comment,
"This is an exciting acquisition for SDI and we plan to explore further applications for the infrared imaging system beyond art restoration".
SDI did indicate in the recent interims that there was improving confidence across the whole of their business spectrum;whilst ProReveal,as Nick2008 believes,could be the catalyst for finally raising SDI's profile and profitability to much higher levels.
As any increase in revenues/margins will impact directly on the SDI bottom line,those invested here could be due a goodly measure of excitement and reward over both the short and medium term.
imo.

[adamb1978] 14/2/2014 10:44

Nigel
Its only a minor quibble but given EBITDA should be moving up towards £1m this year and certainly hit £1m in FY15, then I would have thought that moving from their recent £400k cash position to £600k net debt wouldnt have been too much to ask. Had they been issuing more than 10% of the co then I would have been more annoyed and actually one thing I like about SDI is the board is very sensible for such a small cap co. All will be forgiven if this years figures turn out well!

[gnnmartin] 14/2/2014 08:44

Adam, it's not long since they raised money by placing shares at 15p because their debt was looking a bit dangerous. I think they've got the balance right.
Nigel Martin

[adamb1978] 14/2/2014 07:44

£1m acquisition announced this morning.



Just over 10x PE based on initial consideration, with a further £300k earn-out. Looks sensible and well-priced, though would have preferred them to finance it all by cash/debt rather than partly in shares

[mudbath] 10/2/2014 12:06

Thanks Nick2008 for that information.
I have been adding whilst the price has been depressed.
Today however the supply seems to have evaporated with the result that any further medium sized buying is currently virtually impossible.

[nick2008] 01/2/2014 09:18

Good morning Mud, Apologies for late reply - been real busy. In the UK they are targeting 250 hospitals / checking centres. ProReveal will be in the £20k-£25k price range with not less than 50% margin - IMHO. They have appointed distributors in many regions outside the UK as well so traction will be there this year - 2014. I'll update the header with long term chart. I'll try to dig some more info on this stock. DYOR Nick.

[mudbath] 14/1/2014 10:32

Nick.
Could you provide any detail on the pricing structure for Pro Reveal ?
Do you have a target for unit sales ?
Cheers,mud.
(Any chance of the "long term"chart in your header)
It was a surprise to me when so many holders exited upon the recent figures, 2014 could indeed be more profitable.I have been buying a few at around 17/18pence on that basis.

[nick2008] 10/1/2014 10:51

I'm here for their ProReveal product mainly along with other existing. That one product - ProReveal - alone can deliver almost same revenue at the rest of the products. The senior mgt know it and are ensuring that it gets all the 'ticks' and selling through distributors. 2014 will be the year where we will see the traction for this product. DYOR Nick.

[nick2008] 10/1/2014 10:48

Serchem uses ProReveal to optimise detergent chemistries to meet decontamination regulations - Daily Laboratory News6th Jan 2014http://www.labbulletin.com/articles/Serchem-uses-ProReveal-to-optimise-detergent-chemistries-to-meet-decontamination-regulations#.Us_Q_GQgGc0

[the oak tree] 21/12/2013 16:44

Sold out too first thing after seeing the results. Better shares else where. Have always been worried over their small margin and lack of (apparent) management business skill increasing their business. Really liked the product but its not a good enough reason to contine.

GLA

[interceptor2] 20/12/2013 16:32

Like shanklin I haven't been holding here since late October, but still watch them with interest. The statement seemed very cautious with the use of the word "should" should result in an improvement in margins and profitability.

ic2...

[adamb1978] 20/12/2013 11:43

Hmmmm disappointing results this morning, though 'just' turnover (!). At least margins were strong and the cost base is under control (and from the management speak, should be coming down more).

On the upside, Chairman and CEO were buying at similar levels only a few months ago, the balance sheet is ungeared and they have a pretty decent looking board for a micro cap.

The question is whether the new products which are spoken about in the results do translate into an improved top line. If the turnover ends up flat for the year or only marginally down y-o-y due to a stronger second half and then they could eek out say just 3%-5% turnover growth next year, then the PE falls to single figures

Agree with others though that the share price will likely drift now for a few months, however the balance sheet should prevent worse I hope

[puku] 20/12/2013 11:23

Shanklin - well done, saw the slow decline but still felt results would be good. Sold out today at a fairly big loss - too often I have hung on to other stocks and hoped for better news that never arrived or took much too long. Learned to take my medicine and move on.

[gnnmartin] 20/12/2013 10:56

I rather regretfully agree with the comments above. I will continue to hold, but can't rationalise that. I've come to expect less revenue from ProReveal. It should help to improve sterilisation and cleansing processes, but once the processes have been improved, ProReveal may only have intermittent use as a periodic check on quality. The periodic quality check may not require a large volume of ProReveal consumables.

I shall keep my eyes shut and my head in the sand until the full year figures are published. A happy ending is still possible.
Nigel Martin

[woodcutter] 20/12/2013 08:52

sold for a small loss. It was always a punt on the Re-veal product and i guess whilst there might be significant demand in the future it's yet to be fully commercialised.

It's all very well emphasising the potential H2 results but i felt this statement wasn't so reassuring.

"The overall effect of the reduced sales but increased gross margin and reduced cost of sales and administrative expenses was a loss of £74,000 (2012: profit £11,000). The basic and fully diluted loss per share was 0.33p (2012: basic and fully diluted earnings per share 0.06p"

Despite good operational gearing they've managed to make a loss and this statement implies they are likely to break even at best as they made a £74K loss even with the costcutting. aimho.

There may be a little consolidation in the share price after these results but i fear it will drift down until they deliver H2 figures.

Won't be revisiting, off my watch list now.

Woody